Back to search

University of Leeds

Activity-Directed Discovery of Inhibitors of the p53/Human-MDM2 Protein–Protein Interaction

Abstract

dc:description.abstract

Methods for the discovery of bioactive small molecules are a constant source of innovation in drug discovery. Typically, medicinal chemists discover molecules in design-make-test cycles and invest equal resources into each molecule regardless of biological function. New and emerging workflows for the rapid discovery of bioactive small molecules aim to redistribute resources to high value, active small molecules. This thesis focuses on developing a discovery workflow that invests resources exclusively in high-value, active molecules, and circumvents limitations of traditional discovery workflows. Chapter 1 gives an overview of modern drug discovery practices and focuses on emerging methods for the integrated and high-throughput discovery of bioactive small molecules. Chapter 1 also outlines the biological and medicinal chemistry of the p53/MDM2 protein–protein interaction, and proposes the PPI as a target for activity-directed small molecule discovery. Chapter 2 describes the development of a computational map for the selection of catalysts in high-throughput reaction arrays. Principal component analysis of a library of 48 DFT-optimised rhodium(II) catalysts was used to build the map from a collection of bespoke computational descriptors. The map was compared to a variety of experimental data sources and found to be a useful tool for interpreting reaction outcomes. Chapter 3 describes the design and implementation of two high-throughput reaction arrays for the activity-directed discovery of inhibitors of the p53/MDM2 protein–protein interaction. 346 microscale reactions were performed and seven products were isolated from the scale-up of hit reaction mixtures. Chapter 4 describes the characterisation of hit molecules identified from the activity-directed synthesis workflow. The products were tested in orthogonal biological assays and four distinct series were found to have low micromolar inhibitory activity of the p53/MDM2 protein–protein interaction. Similarity analysis also demonstrated that the products have promising ligand efficiencies and that the products can provide new starting points for drug discovery.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Leeds
Year dc:date.issued
2020

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Green, Adam Ieuan
Advisors dc:contributor.advisor
  • Nelson, Adam
  • Warriner, Stuart
  • Tinworth, Christopher
ORCID person:identifier.orcid

Rights

Language dc:language.dcterms_iso639_2
eng

Identifiers

dc:identifier.*
Identifier
uk.bl.ethos.819335

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Green, Adam Ieuan. Activity-Directed Discovery of Inhibitors of the p53/Human-MDM2 Protein–Protein Interaction. doctoral thesis, University of Leeds, 2020.